Bio-Techne Corp [TECH] stock prices are up 0.40% to $62.83 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TECH shares have gain 7.46% over the last week, with a monthly amount drifted -4.72%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Techne Corp [NASDAQ: TECH] stock has seen the most recent analyst activity on March 18, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $75. Previously, Robert W. Baird downgraded its rating to Neutral on February 19, 2025, and dropped its price target to $68. On May 22, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $85 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $80 on February 08, 2024. Stifel downgraded its rating to a Hold but $65 remained the price target by the analyst firm on February 02, 2024. UBS started tracking with a Buy rating for this stock on December 07, 2023, and assigned it a price target of $80. In a note dated August 28, 2023, William Blair initiated an Outperform rating.
The stock price of Bio-Techne Corp [TECH] has been fluctuating between $56.60 and $85.57 over the past year. Currently, Wall Street analysts expect the stock to reach $79.67 within the next 12 months. Bio-Techne Corp [NASDAQ: TECH] shares were valued at $62.83 at the most recent close of the market. An investor can expect a potential return of 26.8% based on the average TECH price forecast.
Analyzing the TECH fundamentals
The Bio-Techne Corp [NASDAQ:TECH] reported sales of 1.20B for trailing twelve months, representing a surge of 8.96%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.08 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 61.67 points at the first support level, and at 60.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 63.43, and for the 2nd resistance point, it is at 64.03.
Ratios To Look Out For
It’s worth pointing out that Bio-Techne Corp [NASDAQ:TECH]’s Current Ratio is 3.94. Also, the Quick Ratio is 2.77, while the Cash Ratio stands at 1.1. Considering the valuation of this stock, the price to sales ratio is 8.30, the price to book ratio is 4.77 and price to earnings (TTM) ratio is 63.86.
Transactions by insiders
Recent insider trading involved Herr Amy E., Director, that happened on Feb 14 ’25 when 1860.0 shares were sold. Domestic Partner of Director, JOSHUA MOLHO completed a deal on Feb 14 ’25 to buy 1860.0 shares. Meanwhile, Chief Executive Officer Kelderman Kim sold 13392.0 shares on Jan 27 ’25.
